Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Mather A. Carscallen | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | 9 years |
Sylke Hassel | F | - |
Zellbios GmbH
Zellbios GmbH Pharmaceuticals: MajorHealth Technology Part of PharmaZell GmbH, Zellbios GmbH is a German company that specializes in manufacturing cdmo solutions, supplying specialty api products, and producing anticancer drugs. Zellbios is based in Raubling, DE, and Sylke Hassel has been the CEO of the company since 2022. The company offers a wide range of reliable services for small molecule apis and biopharmaceuticals to innovators. Zellbios also supports innovative agrochemical companies with their apis for fungicides, insecticides, and herbicides in a safe and sustainable way. The company provides cdmo services for highly potent apis and cytotoxics and is an expert in pre-formulated nitroglycerin production.
Axplora
Axplora Pharmaceuticals: OtherHealth Technology Axplora is a German company that focuses on delivering sustainable and technologically advanced API products and services. The private company is based in Raubling, Germany. The company's goal is to benefit people, patients, and the planet. The CEO of the company is Sylke Hassel. | 2 years |
Catalina Lopez-Correa | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Barry Fishman | M | 67 |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Jean Drouin | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Roar Askhein | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Dave Shekhter | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Sharon James | F | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Craig Behnke | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Leslie Ewing | F | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Dave Matthews | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Andrew Nichols | M | - |
Algae-C, Inc.
Algae-C, Inc. BiotechnologyHealth Technology Algae-C, Inc. is a Canadian biotech company that specializes in developing and producing high-value active pharmaceutical ingredients using microalgae. Algae-C's high-value molecules are economical and environmentally sustainable, with applications in the pharmaceutical, nutraceutical, and therapeutic industries. The company's technology addresses multiple manufacturing challenges, including increased drug ingredient costs, supply chain risk, and high environmental impacts. Algae-C's platform is naturally carbon negative and intrinsically reduces risk and cost. The company creates designer algae that produce valuable plant-based ingredients for various industries. The company was founded in 2014 and is the largest algae biosynthetic research company in Canada, with over 34 dedicated researchers, including 16 PhDs. The company was founded in 2015 by Mather A. Carscallen, who has been the CEO since then. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 11 | 91.67% |
Germany | 1 | 8.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Pere Paton
- Personal Network